Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

NET INCOME (LOSS) PER SHARE (Tables)

NET INCOME (LOSS) PER SHARE (Tables)

6 Months Ended

Jun. 30, 2022

Schedule of computation of basic and diluted earnings per share

The following table sets forth the computation of basic and diluted earnings per share (in thousands except per share amounts):


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
EPS Numerator:
Net income (loss)	$	(13,492)	$	(13,821)	$	(40,937)	$	25,679
EPS Denominator—Basic and Diluted:
Weighted-average common shares outstanding		172,147		170,192		171,961		169,997
EPS Denominator—Diluted:
Weighted-average common shares outstanding		172,147		170,192		171,961		169,997
Dilutive effect of stock options, restricted stock units and shares under Purchase Plan		—		—		—		5,915
Weighted-average shares outstanding and common stock equivalents		172,147		170,192		171,961		175,912

Net income (loss) per share
Basic	$	(0.08)	$	(0.08)	$	(0.24)	$	0.15
Diluted	$	(0.08)	$	(0.08)	$	(0.24)	$	0.15

Schedule of antidilutive securities

The potential shares of common stock that were excluded from the computation of diluted net income (loss) per share for the periods presented because including them would have been antidilutive are as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Outstanding stock options		33,081		30,639		33,081		9,469
Restricted stock units		1,191		234		1,191		4
Total		34,272		30,873		34,272		9,473